Table 3.
Association of LPL expression in the subcutaneous adipose and whole blood tissue with risks of NAFLD and liver function traits.
| Drug target | Trait | OR/effect size (95% CI) | P value |
|---|---|---|---|
| LPL (subcutaneous adipose tissue) | NAFLD | 0.711 (0.579, 0.874) | 1.20 × 10−3 |
| Liver fat | −0.117 (−0.213, −0.021) | 0.017 | |
| ALT | −0.004 (−0.009, 0.001) | 0.090 | |
| ALP | −0.009 (−0.015, −0.003) | 5.00 × 10−3 | |
| GGT | −0.004 (−0.009, 0.000) | 0.049 | |
| LPL (whole blood tissue) | NAFLD | 0.946 (0.906, 0.989) | 0.014 |
| Liver fat | −0.117 (−0.213, −0.021) | 1.17 × 10−4 | |
| ALT | −0.002 (−0.003, −0.001) | 4.01 × 10−4 | |
| ALP | −0.004 (−0.004, −0.003) | 2.17 × 10−11 | |
| GGT | −0.002 (−0.004, −0.001) | 3.73 × 10−3 |
Abbreviations: OR, odds ratio; NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transferase.